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Abstract
Background
Hypoglycemia is a very serious complication in patients with type 2 diabetes mellitus
(T2DM) and affects the economic burden of treatment. This study aims to create models of
the cost of treating hypoglycemia in patients with T2DM based upon physician estimates of
medical resource usage.
Methods
Using a literature review and personal advice from endocrinologists and emergency physi-
cians, we developed several models for managing patients with hypoglycemia. The final
model was approved by the consulting experts. We also developed 3 unique surveys to
allow endocrinologists, emergency room (ER) physicians, and primary care physicians to
evaluate the resource usage of patients with hypoglycemia. Medical costs were calculated
by multiplying the estimated medical resource usage by the corresponding health insurance
medical care costs reported in 2014.
Results
In total, 40 endocrinologists, 20 ER physicians, and 30 primary care physicians completed
the survey. We identified 12 types of standard medical models for secondary or tertiary hos-
pitals and 4 for primary care clinics based on the use of ER, general ward, or intensive care
unit (ICU) and patients’ status of consciousness and self-respiration. Estimated medical
costs per person per hypoglycemic event ranged from $17.28 to $1,857.09 for secondary
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and tertiary hospitals. These costs were higher for patients who were unconscious and for
those requiring ICU admission.
Conclusion
Hypoglycemia has a substantial impact on the medical costs and its prevention will result in
economic benefits for T2DM patients and society.
Introduction
Type 2 diabetes mellitus (T2DM) is one of the most serious health problems worldwide, and its
acute and chronic complications have substantial clinical impact on healthcare and society [1].
The global population of diabetes mellitus is expected to grow from 171 million in 2000 to over
366 million people by 2030, with T2DM comprising 90% of all diabetes cases worldwide [2].
The largest proportion of treatment costs for diabetes is attributable to its various complica-
tions [3,4]. Because of therapeutic efforts to maintain target HbA1c, an increasing number of
T2DM patients currently live with the risk of hypoglycemia [5]. Hypoglycemia is one of the
severe and undesirable side effects of aggressive glycemic control, and the cost of managing a
severe hypoglycemic episode is comparable to that of nephropathy and is higher than that of
retinopathy [6]. In the ADVANCE study, during a 5-year median follow-up period, 44.6% of
T2DM patients had minor hypoglycemia and 2.1% had at least 1 severe hypoglycemic event
[7]. The incidence of hypoglycemia in T2DM patients taking oral antidiabetic drugs is 16%-
39% and 35.8% in the U.S. and Europe and Asia-Pacific region, respectively [8–10]. The risk of
severe hypoglycemia was 2 times higher in patients receiving insulin compared to those receiv-
ing oral therapies without secretagogues. In addition, age, female gender, longer diabetes dura-
tion, presence of diabetic retinopathy or neuropathy, and number of glucose-lowering drugs
increased the risk of symptomatic hypoglycemia [11]. Also, hypoglycemia itself has been asso-
ciated with numerous undesirable events with neurological impairment such as cognitive abil-
ity, inpatient mortality, and longer hospital stays [12,13]. Moreover, in previous studies,
treatment costs for hypoglycemia were typically calculated for severe hypoglycemic episodes
alone. These costs had reached over $3,282.30, which is similar to costs for chronic complica-
tions and represents an enormous economic impact on the healthcare system [6]. However,
cost estimation for treating hypoglycemia is complicated because it includes both direct and
indirect medical costs associated with each type of episode, which can drastically vary based on
severity of hypoglycemic symptoms, treatment setting (hospitals or primary care clinics), and
frequency of episodes. Direct medical costs involve costs paid by outpatients and inpatients at
medical institutions and pharmacies for direct treatment of hypoglycemia [14]. However, few
studies have investigated direct medical costs for treating hypoglycemia in real-world clinical
settings, accounting for variance in treatment model, setting (i.e., primary care clinics, outpa-
tients clinics in secondary and tertiary hospitals, or emergency rooms [ERs]), and hospitaliza-
tion in general wards or intensive care units (ICUs).
Therefore, the present study aimed to (1) create models of the cost for treating hypoglyce-
mia based on physician estimates of resource usage for T2DM patients in outpatient or inpa-
tient (including ER or ICU) settings of secondary or tertiary hospitals as well as primary care
clinics and (2) estimate the medical costs associated with treating hypoglycemia based on these
models.
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Materials and Methods
Development of a standard medical model
A hypoglycemic event is defined as a blood glucose level<70 mg/dL or an episode with symp-
toms of low blood glucose levels. The first draft version of a standard medical model for treat-
ing hypoglycemia in patients with T2DM was developed based on local and foreign literature
review. In Korea, there are largely 3 categories of health care system. Firstly, primary health
care is the first stage of health care for outpatient care and usually health promotion centers
and primary care clinics offer this kind of health care. In addition, secondary and tertiary hos-
pital provide professional health care from specialists including both inpatient and outpatient
care. Secondary hospital needs to have at least 4 departments with professional doctors and at
least 30 inpatient beds. Tertiary hospital needs to have a full complement of departments and
specific sub-specialty care with professional doctors and at least more than 500 beds. A patient
is referred from primary health care to a secondary or tertiary hospital when further treatment
and intensive care facilities are required. The second version was developed by obtaining one-
on-one advice from 5 endocrinologists working at secondary and tertiary hospitals and 2
emergency physicians to represent medical practices in the ER. The final version was devel-
oped by revising and complementing the draft model based on the consensus of the expert
advisory council members who confirmed the general medical resources used for treating
hypoglycemia.
Development of a physician questionnaire
We developed the draft version of a questionnaire to investigate medical resource usage
through literature review and the experts’ advice regarding the standard medical model for
treating hypoglycemia. To confirm the validity of the questionnaire, we performed a prelimi-
nary survey including 4 endocrinologists, 2 emergency physicians, and 3 primary care physi-
cians. The number of physicians was equivalent to 10% of the physicians intended for
enrollment. Based on one-on-one interview and feedback received from these physicians, we
revised and complemented the preliminary questionnaire and subsequently created 3 final
questionnaires for endocrinologists, emergency physicians from secondary and tertiary hospi-
tals, and primary care physicians, respectively (S1 File). We specified each question in the ques-
tionnaire to calculate each proportion per step in each type of the standard medical model
according to physician (primary physician, endocrinologist, and emergency physician) and
hospital setting (primary clinic and secondary or tertiary hospital), so the incidence of type of
standard medical model was calculated by multiplying each proportion by step.
Evaluation of medical resources for treating hypoglycemia
We evaluated the medical resource usage for treating hypoglycemia among T2DM patients
using a one-on-one interview-style questionnaire survey of 40 endocrinologists, 20 emergency
physicians from secondary and tertiary hospitals, and 30 primary care physicians. The ques-
tionnaire was designed to estimate average medical resource usage based on the respondent’s
personal experience rather than a retrospective chart review. The medical resource usage
included the incidence of hypoglycemia by the type of standard medical model and the pre-
scription rate of each medical resource, such as laboratory and imaging tests and treatments
including infusions of dextrose in water, monitoring, catheter insertion, intubation, and cardio-
pulmonary resuscitation. Responses were stratified by treatment setting (ER, general ward, or
ICU), patient’s status of consciousness and self-respiration, and treatment department (endo-
crinology or ER). For primary care clinics, including departments of internal medicine,
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endocrinology, and family medicine, only outpatient clinic data were included because patients
with severe symptoms rarely visit such clinics.
Calculation of medical costs
Medical costs per case and type from the standard medical model were calculated using survey
results of medical resource usage and for each group (outpatient/ER/inpatient/ICU) by multi-
plying the investigated medical resource usage by the corresponding 2014 health insurance
medical care expenses (S1 Table). All costs were expressed in U.S. dollars ($) based on the final
exchange rate of July 2015. Medical costs excluded drug costs and were calculated by adding
the patient’s and insurer’s shares of medical costs for health insurance benefits, including cer-
tain uninsured expense items, which insurance do not cover so that a patient pays a total
amount of the expense. The cost of magnetic resonance imaging (MRI) performed for patients
who visited ERs due to hypoglycemia was included as an uninsured expense item. For unin-
sured expense items, uninsured expenses were based on the Health Insurance Review & Assess-
ment Service (HIRA), and the average value of each item classified by type of institution was
calculated and applied. Clinically invalid values, as determined by the expert advisory council,
were handled as missing values, and average costs of relevant items were imputed in place of
missing values. Moreover, for undetermined responses due to lack of understanding a survey
question, cost was calculated by changing to a valid value. Costs for medical resources included
in the survey response for other items were also calculated.
Statistical analyses
All continuous variables were expressed as means (standard deviations [SD]), and categorical
variables were expressed as frequencies with percentages. Differences were analyzed using
ANOVA. P<0.05 represented a statistically significant difference. Statistical analyses were
performed using the PASW Statistics software, version 20.0 for Windows (SPSS Inc., Chicago,
IL, U.S.).
Results
Development of standard medical model
We created 12 standard medical models for secondary or tertiary hospitals (Fig 1) and 4 stan-
dard medical models for primary care clinics (Fig 2); these were developed through local and
foreign literature review and expert consensus. As patients with hypoglycemia might visit an
ER or outpatient clinic, patients were categorized according to the department they visited.
Moreover, as we aimed to develop a standard medical model for treating hypoglycemia, we
excluded asymptomatic patients from those who visited any department for regular check-ups.
Patients visiting outpatient clinics were categorized into 2 types based on the outpatient flow:
patients with hypoglycemic symptoms during regular visits (Type A or B) and patients visiting
hospitals due to a hypoglycemic event (Type C or D). Furthermore, because hospitalization
may have been required after a visit to an outpatient clinic, flow from outpatient to inpatient
care was included (Type B or D). For the ER treatment model, major factors for classification
were level of consciousness, self-respiration ability, and treatment at a general ward, ER, or
ICU. Among patients who visited ERs, conscious patients were discharged home or were
admitted to general wards and then discharged (Type E or F). Unconscious but self-breathing
patients who visited ERs were discharged from general wards (Type G), discharged from ICUs
via general wards (Type H), or died after ICU admission (Type J). Type G also includes uncon-
scious patients who were hospitalized in general wards shortly because they stably recovered
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after dextrose infusion. Unconscious patients who could not breathe independently had the
most severe symptoms and were either treated in ICUs or died (Types I and K or Type L). For
patients admitted to ICUs, improvements in condition often resulted in change of hospitaliza-
tion status; accordingly, we created a flow chart of their general ward status (Type I). Further-
more, as patients might die in ICUs due to lack of improvement, we created a flow chart of
their status from ICUs to death (Type K).
Fig 1. Standard medical model for treating hypoglycemia in patients with type 2 diabetesmellitus. (A) Secondary and tertiary hospitals. (B) Primary
care clinics. Type H: an unconscious patient who could breathe independently and was hospitalized in the intensive care unit and general ward after visiting
the emergency room and receiving treatment; Type I: an unconscious patient who could not breathe independently and was hospitalized in the intensive care
unit and general ward after visiting the emergency room and receiving treatment; Type J: an unconscious patient who could breathe independently, visited
the emergency room, received treatment, was hospitalized in the intensive care unit and subsequently died; Type K: an unconscious patient who could not
breathe independently, visited the emergency room, received treatment, was hospitalized in the intensive care unit, and subsequently died. ICU, intensive
care unit.
doi:10.1371/journal.pone.0151282.g001
Economic Burden of Hypoglycemia in Type 2 Diabetes
PLOS ONE | DOI:10.1371/journal.pone.0151282 March 14, 2016 5 / 11
Calculation of medical costs
On an average, 650.0 patients (mean age, 57.2 years; mean T2DM duration, 7.7 years; men,
45.0%) made regular visits to an endocrinologist per month at outpatient clinics of secondary
and tertiary hospitals, and 433.7 patients (mean age, 56.3 years; mean T2DM duration, 6.9
years; men, 43.5%) made regular visits to a primary care physician per month at primary care
clinics (S2 Table). There was no significant correlation between costs for treating hypoglyce-
mia and the duration of physicians’ clinical experience among the 90 physicians (P = 0.065).
Moreover, the 7 metropolitan regions surveyed showed no significant differences in the inci-
dence of hypoglycemia (P = 0.739). Furthermore, no differences were observed in the dura-
tion of hospitalization between secondary and tertiary hospitals. Tables 1 and 2 present the
medical costs for treating hypoglycemia in secondary and tertiary hospitals and primary care
clinics based on the model type. Among hypoglycemic T2DM patients visiting secondary and
tertiary hospitals, the most common model type observed was Type A (non-severe hypogly-
cemia; 47.01%), which included patients discharged home after receiving treatment for hypo-
glycemic symptoms during a regularly scheduled visit at an outpatient clinic, followed by
Type G (11.31%), which included self-breathing unconscious patients who were hospitalized
in general wards after visiting an ER. In primary care clinics, 82.68% of hypoglycemic patients
presented as Type A. The estimated medical costs per hypoglycemic event ranged from
$17.28 (Type A or C) to $1,857.09 (Type I) for secondary and tertiary hospitals and from
$12.85 (Type A or C) to $136.64 (Type B or D) for primary care clinics. S1A and S1B Fig pres-
ent the specific incidence rates of hypoglycemia in T2DM patients who visited secondary and
tertiary hospitals and primary care clinics according to each step in the standard medical
model. Moreover, Tables A-C in S3 and S4 Tables present survey responses and the calcula-
tion of costs for treating hypoglycemia in T2DM patients who visited secondary or tertiary
Fig 2. Medical costs for treating hypoglycemia in secondary and tertiary hospitals and primary clinics according to model type. ER, emergency
room; ICU, intensive care unit.
doi:10.1371/journal.pone.0151282.g002
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hospitals according to the model type and treatment setting (outpatient, ER, general ward,
and ICU). Medical costs per visit to an outpatient clinic, per admission to a general ward, and
per admission to an ICU were calculated as $17.28, $351.69, and $887.14 per person per epi-
sode, respectively (P<0.001). For medical costs incurred in ERs, the per visit cost for a con-
scious patient, an unconscious but self-breathing patient, and an unconscious and non-self-
Table 1. Medical costs for treating hypoglycemia at secondary and tertiary hospitals according to
model type.
Type Deﬁnition Medical cost
($)
A
(47.01%)
Costs incurred by a patient who returned home after receiving treatment for
hypoglycemic symptoms during a regularly scheduled outpatient clinic visit
17.28
B (8.77%) Costs incurred by a patient who was hospitalized after receiving treatment for
hypoglycemic symptoms during a regularly scheduled outpatient clinic visit
368.96
C
(10.57%)
Costs incurred by a patient who returned home after visiting an outpatient
clinic due to hypoglycemic symptoms
17.28
D (3.15%) Costs incurred by a patient who was hospitalized after visiting an outpatient
clinic due to hypoglycemic symptoms
368.96
E (5.61%) Costs incurred by a conscious patient who returned home after visiting the
emergency room and receiving treatment
123.80
F (4.31%) Costs incurred by a conscious patient who was hospitalized in the general
ward after visiting the emergency room and receiving treatment
475.48
G
(11.31%)
Costs incurred by an unconscious patient who could breathe independently
and was hospitalized in the general ward after visiting the emergency room
and receiving treatment
690.61
H (8.75%) Costs incurred by an unconscious patient who could breathe independently
and was hospitalized in the intensive care unit and general ward after visiting
the emergency room and receiving treatment
1,577.75
I (0.28%) Costs incurred by an unconscious patient who could not breathe
independently and was hospitalized in the intensive care unit and general
ward after visiting the emergency room and receiving treatment
1,857.09
J (0.17%) Costs incurred by an unconscious patient who could breathe independently,
visited the emergency room, received treatment, was hospitalized in the
intensive care unit and subsequently died
1,226.07
K (0.01%) Costs incurred by an unconscious patient who could not breathe
independently, visited the emergency room, received treatment, was
hospitalized in the intensive care unit, and subsequently died
1,505.41
L (0.06%) Costs incurred by an unconscious patient who could not breathe
independently and who died after visiting the emergency department
618.26
doi:10.1371/journal.pone.0151282.t001
Table 2. Medical costs for treating hypoglycemia at primary care clinics.
Type Deﬁnition Medical cost
($)
A
(82.68%)
Costs incurred by a patient who returned home after receiving treatment for
hypoglycemic symptoms during a regularly scheduled outpatient clinic visit
12.85
B (0.28%) Costs incurred by a patient who was transferred to a larger institution's
emergency room after receiving treatment for hypoglycemic symptoms
during a regularly scheduled outpatient clinic visit
136.64
C
(15.62%)
Costs incurred by a patient who returned home after visiting an outpatient
clinic and receiving treatment due to hypoglycemia symptoms
12.85
D (1.42%) Costs incurred by a patient who was transferred to a larger institution's
emergency room after visiting an outpatient clinic due to hypoglycemia
symptoms
136.64
doi:10.1371/journal.pone.0151282.t002
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breathing patient were calculated as $123.80, $338.92, and $618.26 per person per episode,
respectively (P<0.001). Costs of imaging studies, including computed tomography (CT)
or MRI, accounted for the largest proportion of total costs in treating unconscious patients
in ERs.
Discussion
In the present study, we developed standard medical models for treating hypoglycemia in
patients with T2DM and consequently identified 12 model types for secondary or tertiary
hospitals and 4 model types for primary care clinics based on the use of ER, general ward, or
ICU and patients’ status of consciousness and self-respiration. The estimated medical cost
per hypoglycemic event ranged from $17.28 to $1,857.09 for secondary and tertiary hospi-
tals and from $12.85 to $136.64 for primary care clinics. Patients with non-severe hypogly-
cemia mostly visited primary care or outpatient clinics, and per visit costs associated with
these treatment types were markedly lesser compared to those who were admitted; however,
non-severe hypoglycemia could be associated with greater overall costs due to its high inci-
dence (69.53%) in secondary and tertiary hospitals. Moreover, severe hypoglycemic patients
who were unconscious or admitted to an ICU represented a relatively high proportion
(20.63%) of cases in secondary and tertiary hospitals and revealed considerably high costs
per episode.
In the present study, standard medical model Type I—an unconscious patient with severe
hypoglycemia who could not breathe independently and was hospitalized in an ICU and gen-
eral ward after visiting an ER and narrowly discharged—accounted for only 0.28% of cases in
secondary and tertiary hospitals but was associated with costs as high as $1,857.09 per person
per episode. Moreover, from an social and economic viewpoint, even after recovery from
severe hypoglycemia, the risk of accelerated dementia, repeated hypoglycemic events due to
hypoglycemia unawareness, and subsequent fear of hypoglycemia associated with obstacles
for achieving glycemic goals could be responsible for its enormous unmeasured burdens [12].
Conscious patients visiting ERs who did not die or require admission to an ICU and recovered
safely incurred markedly lower costs compared with unconscious patients. In addition,
among hypoglycemic patients visiting secondary and tertiary hospitals, although a majority of
patients (69.53%) had visited outpatient clinics with mild hypoglycemia, unconscious patients
who visited ER and could breathe independently accounted for a relatively large proportion as
well (20.23%) with high associated costs. As patients who have comorbidities such as renal
disease, cardiovascular disease, or pulmonary problems treat for hypoglycemia may require
hospitalization longer or need intensive care, it could confound the cost of hospitalization
[15,16]. However, we focused on the treatment for hypoglycemia alone so, we estimated the
cost of medical resource usage for hypoglycemia, at most. Moreover, hypoglycemia treatment
in outpatient clinics at secondary or tertiary hospitals was more costly compared to the treat-
ment cost at primary care clinics. A previous study reported that the cost of hypoglycemia
depends on the severity of the episode: for example, the annual cost per patient per episode
increased from $366.20 for cases of moderate hypoglycemia, wherein a patient seeks medical
attention for hypoglycemia but is not admitted overnight to a hospital, to $3180.33 for severe
hypoglycemic events requiring hospitalization [17]. Ha WC et al. reported that the average
medical cost incurred for severe hypoglycemia ranged from $135.50 to $1,391 in Korea, with
costs for hospitalization and brain imaging comprising the largest proportion of total costs
[18]. However, no study on medical costs has been conducted for each specific type after
admission to a hospital, such as ICU care. Of note, the present study demonstrates that esti-
mation of direct medical costs for hypoglycemia, particularly for cases previously defined as
Economic Burden of Hypoglycemia in Type 2 Diabetes
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severe hypoglycemia requiring hospitalization, varies considerably depending on the details of
treatment settings, consciousness, and ability to breathe independently. In addition, we pre-
sented differences of incidence and costs by type for secondary and tertiary hospitals, and pri-
mary care clinics.
The present study has several distinguishing strengths. For development of standard medi-
cal models of hypoglycemia, we used an incidence-based approach in relation to all existing
cases in primary care clinics and secondary or tertiary hospitals, along with the possible treat-
ment approaches, via the consensus of an expert advisory council. Therefore, we were able to
identify and involve a series of specific, step-by-step treatment processes only for hypoglycemia
in terms of real-world clinical practice. Based on these models, we could estimate the costs, not
only for each step of a model type but also total costs per type. We also demonstrated represen-
tative results derived from a large population in 7 different metropolitan areas from a total of
90 specialized experts with extensive clinical practical experience.
The present study has several limitations. First, in the questionnaire, data were recorded
based on the respondent’s personal experience rather than a retrospective chart review.
Therefore, there might be some recall bias in the data reported in terms of incidence of med-
ical resource usage. However, data were collected from 90 medical experts from various spe-
cialties and extensive clinical experience: the 40 endocrinologists, 20 emergency physicians,
and 30 primary care physicians had a mean clinical experience of 13.9, 12.7, and 20.0 years,
respectively. Second, for medical resource usage, although laboratory and imaging tests and
treatments were included, drug costs were not included in the calculated medical costs;
hence, the actual costs were probably underestimated. Last, we could not estimate the overall
annual direct medical costs for hypoglycemia in Korea, which could have been calculated
only by knowing the exact prevalence of hypoglycemia. Recently, the prevalence of symp-
tomatic hypoglycemia in patients with T2DM in Korea was reported as 39.0%, but addi-
tional studies are warranted to determine the incidence of hypoglycemia for accurate
estimation [9]. Moreover, we could not use real patients and assess real costs using National
Health Insurance Service (NHIS) database, because it was not able to solely assess the real
medical costs for treating hypoglycemia due to mixed medical costs including costs for treat-
ing other underlying disease, comorbidities, or adverse effects. Also, its discrepancy between
diagnosis of individuals in real-practice and recorded in the claim database could show
inconsistent and inaccurate estimation for hypoglycemia. Therefore, we assessed medical
cost by various model types and focused on the costs only for treating hypoglycemia includ-
ing laboratory and imaging tests and treatments based upon physician estimates of medical
resource usage.
Conclusion
In conclusion, we developed standard medical models for treating hypoglycemia in patients
with T2DM: 12 model types for secondary or tertiary hospitals and 4 model types for primary
care clinics. In addition, we evaluated medical resource usage and estimated direct medical
costs per hypoglycemic event in order to estimate the real practical patterns and economic bur-
den of hypoglycemia. The direct medical costs for hypoglycemia were particularly high for
patients who were unconscious upon presentation and for those admitted to ICUs. It is clear
that hypoglycemic events among patients with T2DM are associated with a considerable finan-
cial cost, and thus, prevention of these events can reduce the overall healthcare expenditure
incurred by such patients. Therefore, glycemic control strategies and therapeutic regimens
must be carefully selected with individualized patient considerations to prevent hypoglycemia
in patients with T2DM.
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